A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Neeta Somaiah, Brian Andrew Van Tine, Bartosz Chmielowski, Joseph J. Drabick, Sant P. Chawla, Meredith McKean, Alexander I. Spira, Kenneth John O'Byrne, Steven A. Foresto, Sujana Movva, AeRang Kim, Brian Gastman, Joseph Gerald Pressey, Ben Paudyal, Asit De, Robert E. Winkler, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai
Institutions: The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center, Sarcoma Oncology Center, Sarah Cannon, Tennessee Oncology, Virginia Cancer Specialists, Queensland University of Technology, Princess Alexandra Hospital, Children's Health Queensland Hospital and Health Service, Memorial Sloan Kettering Cancer Center, Children's National, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cincinnati Children's Hospital Medical Center, Ascentage Pharma Group Inc. (United States), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379282831